Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firuglipel Phase 2 Dose Finding in Japanese T2DM
NCT02628392Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of firuglipel in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in HbA1c at 12 weeks. Started Nov 2015; status: completed.
02
Drugs
firuglipel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02628392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02628392.